Yakira Capital Management’s NRX Pharmaceuticals NRXP Stock Holding History

Yakira Capital Management’s Portfolio NRXP Stock Details NRXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,192	Closed	-$139K	–	396
2021 Q2	$139K	Buy	+1,192	New	+$315K	0.02%	287
2020 Q4	–	Sell	-1,641	Closed	-$176K	–	277
2020 Q3	$176K	Hold	1,641	–	–	0.05%	175
2020 Q2	$172K	Hold	1,641	–	–	0.08%	119
2020 Q1	$177K	Sell	1,641 -14,859	-90%	-$1.59M	0.06%	110
2019 Q4	$1.75M	Hold	16,500	–	–	0.51%	49
2019 Q3	$1.75M	Hold	16,500	–	–	0.51%	51
2019 Q2	$1.72M	Hold	16,500	–	–	0.34%	62
2019 Q1	$1.71M	Hold	16,500	–	–	0.49%	54
2018 Q4	$1.68M	Hold	16,500	–	–	0.57%	47
2018 Q3	$1.65M	Hold	16,500	–	–	0.31%	67
2018 Q2	$1.64M	Hold	16,500	–	–	0.4%	54
2018 Q1	$1.62M	Hold	16,500	–	–	0.37%	51
2017 Q4	$1.6M	Buy	+16,500	New	+$1.6M	0.52%	38

Other funds holding NRXP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

OCAM

Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HAG

HighPoint Advisor Group Downers Grove, Illinois $2.39B AUM 28.86% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Yakira Capital Management's NRXP Position: Q3 2021 in Review

Yakira Capital Management sold out of NRX Pharmaceuticals (NRXP) in Q3 2021, closing a stake of 1,192 shares — an estimated $139K sold.

Yakira Capital Management first reported a position in NRXP in Q4 2017 and held it in 13 quarters. The position peaked at $1.75M in Q4 2019. 23 funds tracked by Wall St. Rank hold NRXP as of Q3 2021.

Yakira Capital Management reported no remaining NRX Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Yakira Capital Management sold 1,192 NRX Pharmaceuticals shares in Q3 2021, an estimated $139K.
Yakira Capital Management first reported a position in NRX Pharmaceuticals in Q4 2017 and held it in 13 quarters.
Yakira Capital Management's NRX Pharmaceuticals position peaked at $1.75M in Q4 2019.
23 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q3 2021.

Based on Yakira Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.